KR100852965B1 - 피페라진디온 화합물 - Google Patents

피페라진디온 화합물 Download PDF

Info

Publication number
KR100852965B1
KR100852965B1 KR1020027015025A KR20027015025A KR100852965B1 KR 100852965 B1 KR100852965 B1 KR 100852965B1 KR 1020027015025 A KR1020027015025 A KR 1020027015025A KR 20027015025 A KR20027015025 A KR 20027015025A KR 100852965 B1 KR100852965 B1 KR 100852965B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
piperazinedione
dione
methylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027015025A
Other languages
English (en)
Korean (ko)
Other versions
KR20030005336A (ko
Inventor
체-밍 텡
후이-포 왱
에릭 아이. 시. 리
온 리
지-화 구
훼이-팅 첸
얀-빙 판
야-란 첸
Original Assignee
애드파르마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애드파르마 인코포레이티드 filed Critical 애드파르마 인코포레이티드
Publication of KR20030005336A publication Critical patent/KR20030005336A/ko
Application granted granted Critical
Publication of KR100852965B1 publication Critical patent/KR100852965B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
KR1020027015025A 2000-05-09 2001-05-08 피페라진디온 화합물 Expired - Fee Related KR100852965B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09
US60/304,191 2000-05-09
PCT/US2001/014721 WO2001095858A2 (en) 2000-05-09 2001-05-08 Piperazinedione compounds

Publications (2)

Publication Number Publication Date
KR20030005336A KR20030005336A (ko) 2003-01-17
KR100852965B1 true KR100852965B1 (ko) 2008-08-19

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027015025A Expired - Fee Related KR100852965B1 (ko) 2000-05-09 2001-05-08 피페라진디온 화합물

Country Status (14)

Country Link
US (1) US6635649B2 (https=)
EP (1) EP1282609B1 (https=)
JP (1) JP5101781B2 (https=)
KR (1) KR100852965B1 (https=)
CN (1) CN100522949C (https=)
AT (1) ATE417614T1 (https=)
BR (1) BR0110745A (https=)
CZ (1) CZ301743B6 (https=)
DE (1) DE60137037D1 (https=)
HU (1) HUP0302358A3 (https=)
NO (1) NO326341B1 (https=)
RU (1) RU2269520C2 (https=)
WO (1) WO2001095858A2 (https=)
ZA (1) ZA200209917B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
CN100553636C (zh) 2000-08-04 2009-10-28 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2004030522A2 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
EP2517718B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
CA2538352A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize n-acyl-l-aspartic acid
AU2005212399B2 (en) * 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
CN102131775B (zh) * 2008-08-22 2015-12-16 不列颠哥伦比亚癌症局分支机构 雄激素受体n-末端活化的小分子抑制剂
CN102395581A (zh) * 2009-04-16 2012-03-28 泰立克公司 作为微管蛋白聚合抑制剂的取代的4-氨基-5-苯甲酰基-2-(苯基氨基)噻吩-3-腈和取代的4-氨基-5-苯甲酰基-2-(苯基氨基)噻吩-3-羧酰胺
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021832A1 (en) * 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
US4806538A (en) * 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 １−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021832A1 (en) * 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Chem. Soc. Perkin Trans. 1990, 2, 1, 127-132
Tetrahedron Letters, 1991, 32(47), pp. 6883-6884
Tetrahedron, 1999, 55(22,28), pp. 6841-6846

Also Published As

Publication number Publication date
WO2001095858A2 (en) 2001-12-20
ZA200209917B (en) 2004-04-28
CN100522949C (zh) 2009-08-05
CZ20023693A3 (cs) 2003-05-14
ATE417614T1 (de) 2009-01-15
NO20025373L (no) 2002-12-13
NO326341B1 (no) 2008-11-10
JP5101781B2 (ja) 2012-12-19
KR20030005336A (ko) 2003-01-17
JP2004510701A (ja) 2004-04-08
WO2001095858A3 (en) 2002-03-21
DE60137037D1 (de) 2009-01-29
EP1282609A4 (en) 2003-06-04
BR0110745A (pt) 2003-12-30
HUP0302358A2 (hu) 2003-11-28
HUP0302358A3 (en) 2007-09-28
CN1441789A (zh) 2003-09-10
CZ301743B6 (cs) 2010-06-09
EP1282609B1 (en) 2008-12-17
EP1282609A2 (en) 2003-02-12
NO20025373D0 (no) 2002-11-08
US20020028819A1 (en) 2002-03-07
RU2269520C2 (ru) 2006-02-10
US6635649B2 (en) 2003-10-21

Similar Documents

Publication Publication Date Title
KR100852965B1 (ko) 피페라진디온 화합물
Chang et al. Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinylquinoline derivatives
US7507762B2 (en) Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2002508007A (ja) Ｍｄｒモジュレーターとしてのイミダゾール誘導体
WO2004101570A1 (en) Sulfur-containing naphthoylimide derivatives
US7288545B2 (en) Piperazinedione compounds
BRPI0617364A2 (pt) compostos heterocÍclicos como inibidores de pstat3/il-6
CN103429586A (zh) 哌嗪二酮化合物
KR100819576B1 (ko) 신규 찰콘 화합물
AU2001294505B2 (en) Piperazinedione compounds
CA2408649C (en) Piperazinedione compounds
AU2001294505A1 (en) Piperazinedione compounds
EP3008073B1 (en) Thieno[2,3-b]pyridines as multidrug resistance modulators
US20060040909A1 (en) Selenophene compounds
CN112824405B (zh) 一种n-甲基依诺沙星的丙烯酮衍生物及其制备方法和应用
EP1270008B1 (en) Fused tricyclic analogues of guanosine for treating tumors
US20250163002A1 (en) Fused quinonoxime imidazole, onium derivatives thereof, preparation and use thereof
KR101357395B1 (ko) 신규한 테트라졸로 하이드라존 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
CN111303025A (zh) 一种n-乙酰基氟罗沙星的丙烯酮衍生物及其制备方法和应用
Al-Harbi et al. Full Text HTML

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20110819

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120821

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130813

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130813